Skip to main content

ACR21 Best Abstracts - Day 4

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these as their favorite reports:

  1. DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the rheumatoid disease properly is the current best strategy for treating RA-ILD. Abstract #1918
  2. Composite MACE outcomes no different among PsA pts treated w/ biologics and DMARDs. Abstract 1833 
  3. The wave of the future? Study details immune profile which discriminates PsA from PsO using phenotyping of serum immune cell subsets & machine learning. Abstract# 1774 
  4. Breakthrough infections (BTI) in Rheum pts: USA EMR (N3C) Data on 577,335 Rheum Pts w/ 18,164 #COVID19 BT) - 91% vax'd, 3.1% BTIs, BTI higher in inflamm myositis, RA, Gout, vasculitis and with biologics, multiple DMARDs  Abstract# L16
  5. What to do w Rituximab users and #COVID19 vaccine? #Rituximab no seroconversion in 30% with 2 COVID Vaccination. With 3rd vaccine dose, up to 94% can have immune response! Pts need their 3rd vaccination. Abstract# L17
  6. Should we be measuring drug levels in pts taking infliximab? NOR-Drum Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (iin RA, PsA, SpA, UC, Crohn's, PsO pts) Abstract#946  
  7. An artificial neural network for detection of radiographic #sacroiliitis in axSpA? Specificity - 93.9%; sensitivity - 78.7%  Potential tool for interpreting SIJ in nonspecialized centers or clinical trials. This is a game changer! Abstract# 1919
  8. Advantages of treat to target (of serum urate) beyond less gout flares? Maybe less MACE events. Modeling observational study Abstract# L06 
  9. TitAIN study of IL-17 inhibitor secukinumab for GCA. Phase 2 RCT, 52 patients. In combination 26-week GC taper. Sustained remission, at week 28 - 70% SEC vs 20% placebo, week 52 - 59% vs 8%. Less steroids, less adverse events in secukinumab group.
  10. Emapalumab in MAS.  A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction. Abstract# L20  
  11. Increased pregnancy complications in axSpA in Irish registry. 41.9% complicated, 11.4% pregnan w/multiple complications. Miscarriage 20.5%. Amongst live births 10.8% c-section, preterm 11.4% . NICU admiss 11.4%. Downwards arrow breastfeeding rate at 33.7%  Abstract# 0369
  12. Interim analysis of AURORA 2 Extension study: Voclosporin maintained meaningful reductions in UPCR and eGFR remained stable until month 30. No unexpected new  Abstract# 1425
  13. Anti-MAA Ab is not ‘baa’ humbug. In prevalent #RheumatoidArthritis, + MAA Ab was predictive of developing #RA #ILD. ?  Novel biomarker. Needs validation but nice convincing data  Abstract#1916
  14. Retrospective cohort study FORWARD databank – More opioid use was associated with higher HAQ-DI and BASDAI scores among patients with PsA or AS.  Annualized avg opioid use and costs  increased with higher HAQ-DI and BASDAI scores for patients in both cohorts  Abstract# 1117
  15. GLORIA study of adding prednisolone 5mg to DMARDs over 2 years for RA in those >65 years. Mean DAS 0.37 points lower, Sharp score 1.7 lower (are either of these clinically significant?). NNH 9.5. To me causing harm chasing statistical benefit Abstract# 1678
stillsNow cTA


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject